Description
Ultibro Brizchailer
Ingredients
- Ultibro Brizchailer contains glycopyrronium and indacaterol as active ingredients.
- Glycopyrronium is an anticholinergic bronchodilator.
- Indacaterol is a long-acting beta agonist (LABA).
Dosage
The recommended dosage of Ultibro Brizchailer is one capsule (110 mcg glycopyrronium/50 mcg indacaterol) to be inhaled once daily using the provided inhaler.
Indications
Ultibro Brizchailer is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD).
Contraindications
Ultibro Brizchailer is contraindicated in patients with a hypersensitivity to glycopyrronium, indacaterol, or any other components of the product.
Directions
- Remove one capsule from the blister pack and place it in the inhaler.
- Inhale the contents of the capsule through the mouthpiece once daily at the same time each day.
- Do not swallow the capsules.
Scientific Evidence
Studies have shown that Ultibro Brizchailer provides superior bronchodilation compared to its individual components. It has been demonstrated to improve lung function and quality of life in COPD patients.
Additional Information
- Regularly clean the inhaler device for proper functioning.
- If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not take a double dose.
Pharmacological Effects: Ultibro Brizchailer works by targeting two pathways in the lungs for bronchodilation. Glycopyrronium blocks acetylcholine action, while indacaterol stimulates beta receptors.
Clinical Trials: Comparative studies have shown Ultibro Brizchailer to be more effective in improving lung function and reducing exacerbations in COPD patients compared to other bronchodilator therapies.
